 Office of Technology Management
The Salk Institute's Office of
Technology Management (OTM)
supports the Institute by managing
intellectual property discovered
by Institute scientists. This intellectual
property advances the Institute's
mission to improve human health
by transferring basic research
discoveries made in the laboratories to the marketplace for commercial development.
To that end, OTM works with the faculty to begin the patenting process for research discoveries, negotiates and administers technology licenses, and facilitates industry collaboration and sponsored research.
Technology management at the Institute has resulted in over 350 U.S. patents and more than 250 license agreements with pharmaceutical, biotechnology, and reagent supply companies. In addition, 22 startup companies have been founded to develop Institute technology, including Ligand Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., Signal Pharmaceuticals (acquired by Celgene Corporation) and SIBIA Neurosciences (acquired by Merck and Co., Inc.). OTM is also fostering new startup activity for technologies to treat diabetes and neurological diseases, as well as for understanding the effects of aging.
Interested in more information about a technology? Submit your request here.
|
- Lunch and Learn Seminars (videos and presentations)
- FYIs
|
|
|
Michael T. White, Ph.D., CLP
Interim Director, OTM
Phone Extension: 1703
mwhite@salk.edu
Pam Bock
Material Transfer Agreement Coordinator
Phone Extension: 2006
bock@salk.edu
Justin Carlson, Ph.D.
Licensing Intern
Phone Extension: 1278
jcarlson@salk.edu
Karen Cotton
Marketing Associate
Phone Extension: 1758
cotton@salk.edu
|
Carol Dykman
Licensing Coordinator
Phone Extension: 1481
dykman@salk.edu
Sheila Kirschenbaum, Ph.D., J.D.
Patent Counsel
Phone Extension: 1612
kirschenbaum@salk.edu
Constance Mueller
Patent & License Administrator
Phone Extension: 1119
cmueller@salk.edu
Dave Odelson, Ph.D.
Senior Licensing Executive
Phone Extension: 1223
dodelson@salk.edu
|
|
|
